Frontage Laboratories acquires Concord Biosciences

Frontage Laboratories, a global CRO with headquarters in Exton, Pennsylvania, has announce the acquisition of Concord Biosciences, formerly known as Ricerca Biosciences, a preclinical CRO located near Cleveland, Ohio. Founded in 1986, Concord Bio supports the pharmaceutical, agricultural, chemical and animal health industries with Drug Safety, Metabolism, Bioanalytical, Residue and Environmental Fate studies.
Dr Song Li, founder and CEO of Frontage Laboratories, said, “We have committed to build a global CRO company with integrated services. The acquisition of Concord Biosciences is a significant step toward reaching our goal. The addition of Concord Bio to the Frontage family will enable us to provide pharmaceutical product development services from lead selection to IND-enabling studies to commercialization. Additionally, the agrochemical expertise of Concord Bio will position Frontage as a major CRO in the agricultural products industry.”